Charles Schwab Investment Management Inc Arcus Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 566,979 shares of RCUS stock, worth $9.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
566,979
Previous 507,443
11.73%
Holding current value
$9.02 Million
Previous $7.73 Million
12.18%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
51.5MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$155 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$87 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$55.3 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$47.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$38.8 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.15B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...